Tianhong Li, M.D., Ph.D. for UC Davis Health

Tianhong Li, M.D., Ph.D.

Professor, Department of Internal Medicine, Division of Hematology and Oncology

To see if Tianhong Li is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).



Lung Disease

Breast Disease


Internal Medicine

Locations and Contact

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center
4501 X St.
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone


Clinic Fax


Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Li sees each patient is unique and would like to support her patients through the journey fighting cancer. Dr. Li believes in a multidisciplinary team approach to provide the best cancer care to individual patients. She provides her patients the most state-of-the-art cancer care, including the option of participating in promising clinical trials.

Clinical Interests

Dr. Li is a board-certified, practicing medical oncologist specialized in experimental therapeutics focusing on lung cancer and breast cancer at the UC Davis Comprehensive Cancer Center (UCDCCC). She also attends lung cancer clinic at VA Northern California Health Care System (VANCHCS).

Research/Academic Interests

Dr. Li is interested in personalized cancer care by applying her extensive laboratory and clinical research knowledge. Her career goal is to translate innovative treatment strategies and technology advances into direct patient care through early phase clinical trials. Her current research focuses on understanding the primary and acquired resistance mechanisms of cancer therapy and improving tissue and blood-based molecular and immune biomarkers for precision lung cancer therapy.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Medical School

M.D., Beijing University School of Medicine, Beijing, China 1989

Other School

Ph.D., Microbiology and Immunology, Loyola University, Stritch School of Medicine, Maywood IL 1996


Internal Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine, New York NY 1997-1998


Internal Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine, New York NY 1998-2000


Hematology/Oncology, Montefiore Medical Center, Albert Einstein College or Medicine, Bronx NY 2003

VA Merit Award, 2021, 2022, 2023, 2024, 2025

Top Doctors in Hematology and Oncology, Sacramento Magazine, 2020

First Prize Poster Award, the 17th Annual Cancer Research Symposium, UCD Cancer Center, 2013

K12 Scholar, Clinical and Translational Science Center (CTSC), UC Davis School of Medicine, Sacramento CA, 2009, 2010, 2011, 2012

Young Investigator Award, Southwest Oncology Group (SWOG), The Hope Foundation, Seattle WA, 2010

To view a detailed list of  Dr. Li's publications, please click here.

Ma W, Zeng J, Chen S, Lyu Y, Toomey KA, Phan CT, Yoneda KY, Li T. Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. Biomark Res. 2021 Sep 6;9(1):69. doi:10.1186/s40364-021-00324-6. PMID:34488906

Li Q, Ma W, Chen S, Tian EC, Wei S, Fan RR, Wang T, Zhou C, Li T. High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer. Transl Lung Cancer Res. 2020 Aug;9(4):1361-1378. doi:10.21037/tlcr-19-633. PMID:32953510.

Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019 Jun 10;12(1):56. doi:10.1186/s13045-019-0740-7. Erratum in: J Hematol Oncol. 2019 Jul 26;12(1):83. PMID:31182116.

Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019 Jun;8(3):286-301. doi:10.21037/tlcr.2019.04.14. PMID:31367542.

Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):60-67. doi:10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28. PMID:27919627.

Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016 May 27;9(1):47. doi:10.1186/s13045-016-0277-y. PMID:27234522.

Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol. 2016 Mar 10;9:23. doi:10.1186/s13045-016-0254-5. PMID:26966027.

Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10;31(8):1039-49. doi:10.1200/JCO.2012.45.3753. Epub 2013 Feb 11. PMID:23401433.

Li T, Guo M, Gradishar WJ, Sparano JA, Perez EA, Wang M, Sledge GW. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012 Jul;134(1):345-52. doi:10.1007/s10549-012-2071-z. Epub 2012 May 1. PMID:22547107.